IRBM’s Post

🎤The abstract submissions now extended to 6 March. The overarching theme for the 19th AVPC is 'Translating Science into Effective Management’ – a big topic, we know! To help guide your abstract submissions, we’ve developed 16 sub-themes ranging from collaboration and community coordination to biotechnology and genetic biocontrol. Find out more about these themes and how to submit an abstract at https://loom.ly/eVQcUL0 #AVPC2024

New Blog Alert!! On our new Research Updates Blog, we will be sharing layperson-friendly summaries of recent publications about DYNC1H1, dynein, and biotechnology research. This first post highlights results of the Diagnostic Odyssey Survey. This was only possible because of patients in our Contact Registry filling out the survey. Haven’t registered yet? Do so at: dync1h1.org/registry. Thank you to those who participated! If you forgot to complete the survey, it’s not too late! Check out the blog at: https://lnkd.in/ejHM4ipF #dync1h1 #researchupdates #raredisease

New passport (finally) arrived ! Ready to go. Join me and my colleagues Maria Pia Catalani and Alessandro Cinti at BOOTH 410 to discuss the latest innovations in drug discovery and the way Axxam might support your next Research program. But that's not all! Don’t miss Alessandro’s 30-minute talk on Targeted Protein Degradation (TPD): A New Frontier in Drug Discovery: 🧬 Abstract: Targeted Protein Degradation (TPD) offers a novel approach to modulate the intracellular levels of disease-causing proteins. Here, we will delve into the practical aspects of TPD, focusing on the development and implementation of cell-based assays aimed at monitoring target protein levels, and will discuss how complementary cell-based and cell-free assays support the discrimination of unspecifically-interfering compounds and detailed characterization and further development of hit compounds. 📅 Date: October 2, 2024 📍 Location: Boston, MA, USA #DiscoveryOnTarget2024 #DoT #TargetedProteinDegradation #TPD #Innovation #DrugDiscovery

In 1973, Stanley Cohen, Herbert Boyer, Annie Cheng, and Robert Helling published "Construction of Biologically Functional Bacterial Plasmids In Vitro," their landmark paper on Recombinant DNA that many consider the intellectual seed for the biotechnology industry. In that seminal paper, the key restriction enzyme that allowed for the creation of the new, Recombinant plasmid DNA species was EcoRI. In this 51st year since their breakthrough publication, it may serve us to ask how our organizations can cultivate a recombinant engineering and design culture inspired by the EcoRI enzyme, catalyzing intellectual exchange and incorporating genes of interest from disparate fields into transformative technologies. https://lnkd.in/g9J_53RJ

The image illustrates the process of creating recombinant DNA using plasmids and the restriction enzyme EcoRI. The key steps shown are: 1. Plasmid DNA and foreign DNA (region of interest) are cut by the EcoRI enzyme at specific recognition sites. 2. The resulting sticky ends allow the foreign DNA to hybridize with the plasmid DNA, forming a recombinant DNA molecule. 3. The recombinant DNA is then inserted into a bacterial cell, where it can be cloned and replicated. 4. Through cloning, multiple copies of the recombinant DNA containing the foreign gene of interest are produced. This groundbreaking technique, first published in 1973, laid the foundation for the biotechnology industry by enabling the incorporation of desired genes into bacterial or other host cells for various applications like protein production, genetic engineering, and more. The analogy of cultivating a "recombinant engineering and design culture" inspired by EcoRI enzyme highlights the importance of promoting intellectual exchange, cross-pollination of ideas from diverse fields, and integrating novel "genes of interest" (concepts, techniques, perspectives) into transformative technologies and innovations. Just as EcoRI facilitated combining DNA from different sources, organizations should foster an environment that encourages collaboration, knowledge sharing, and the recombination of ideas across disciplines and domains. This mindset can catalyze the creation of disruptive solutions by integrating disparate concepts into novel applications, much like recombinant DNA revolutionized biotechnology.

Alcami Corporation's Solid-State Characterization team has the expertise to design and execute crystal-form screening workflows and to comprehensively evaluate novel API forms. A solid-state study, including identification of new chiral modification of a long-known drug, guaifenesin, and detailed characterization and quantification were all part of a recent publication in “Crystal Growth and Design” titled: “Discovery, Characterization, and Solid-State Quantification of the Racemic Compound of Guaifenesin” Congratulations to Joanna Bis, Briana Graves, Frank Tarczynski, and Lukasz Wojtas on this publication! Read the article ➡️ https://hubs.li/Q02BxB4q0 #SolidStateCharacterization #Crystalformscreening #SolidStateQuantification #Discovery #casestudy #artinspiration #racemiccompound #smallmolecule #crystallization #CDMO #Alcami #research #APIscreening #published

Great to see Big4Bio highlight one of our recent case studies, where researchers at the The University of Texas at Austin used ENFINIA DNA to engineer long, complex polyketide molecules, saving them weeks. Polyketides are a source of bio-active molecules representing approximately 20% of top-selling drugs. As valuable as previously isolated polyketides have proven to be, the rise of antibiotic-resistant microorganisms and the demand for novel anti-infective and anticancer treatments underscore the necessity for additional polyketides. Given their diverse and targeted biological effects, exploring new polyketides remains an important and active area of research. ELEGEN is proud to aid Dr. Adrian Keatinge-Clay’s lab and accelerate their pursuit of novel polyketides. Read more: https://bit.ly/3WfoARl #polyketides #genesynthesis #syntheticDNA #EnfiniaDNA

I'm delighted to share that another article of my team on drug development has been published today in the reputed Journal of Natural Product Research (Q1, IF: 1.9, CS: 5.9, Publisher: Taylor and Francis). Title: Piperine exerts anti-inflammatory effects and antagonizes the properties of celecoxib and ketoprofen: in vivo and molecular docking studies Research Impact: Piperine a natural product having antiinflammatory activity. Our research also demonstrated that piperine has anti-inflammatory effects in chicks through COX-2 inhibition pathways and antagonizes the anti-inflammatory activity of established drugs such as celecoxib and ketoprofen. Concerns are required to use the combination of piperine with these drugs.

I am happy to say that after 3 years of waiting, my article has finally been published “Assessment of the efficiency and stability of enzymatic membrane reaction utilizing lipase covalently immobilized on a functionalized hybrid membrane” in Journal of Biotechnology. The aim of this article was the covalent immobilization of lipase enzyme on the hybrid membrane, which enabled the stability and reuse of this enzyme. Thanks to all my colleagues and professor who accompanied me in this path🙏🏻🌺. https://lnkd.in/d4KGGyRM

𝐍𝐮𝐜𝐥𝐞𝐢𝐜 𝐀𝐜𝐢𝐝 𝐈𝐬𝐨𝐥𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐏𝐮𝐫𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $9.4 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dRTNscQj The global nucleic acid isolation and purification market in terms of revenue was estimated to be worth $6.4 billion in 2023 and is poised to reach $9.4 billion by 2028, growing at a CAGR of 8.1% from 2023 to 2028. 𝐓𝐨𝐩 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 Thermo Fisher Scientific QIAGEN Merck Wohlfahrtsstiftung der F. Hoffmann-La Roche AG Promega Corporation Agilent Technologies, Danaher Corporation Bio-Rad Laboratories, Illumina. Takara Bio Inc. New England Biolabs abcam Kilpest India Ltd. Apical Scientific Sdn Bhd. Endress+Hauser Group Genaxxon bioscience GmbH LGC Biosearch Technologies Zymo Research Corp Norgen Biotek Omega Bio-tek, TIANGEN BIOTECH (BEIJING)CO LTD. AutoGen, Inc. PCR Biosystems Biogenuix Medsystems Pvt Ltd #nucleicacid #molecularbiology #biotechnology #genomics #dnaisolation #rnaisolation #labtech #lifesciences #biomedicalresearch #scientificresearch #geneticresearch #pcr #biotech #labequipment #clinicalresearch